Bob Pooler

Bob Pooler is an analyst at Valuation Lab, where he provides insights on pharmaceutical developments. Recently, he has been in the news for his optimistic assessment of Cosmo's potential hair growth medication, Breezula, predicting significant market success and annual revenues of up to 2.5 billion euros if the product secures a strong distribution partner.